Drug intelligence / Profile preview

JT-001 + JT-002

Development stage: Preclinical
Lead developer: Genentech
Modality: Small Molecules
Administration: Oral

Overview

JT-001 + JT-002 is a combination of two investigational small molecule drugs, both developed as **NLRP3 inflammasome inhibitors**. JT-001 and JT-002 are both being studied for their ability to block NLRP3-dependent inflammatory cytokine production, notably IL-1β, suggesting utility in autoinflammatory and metabolic diseases. JT-001 was developed for nonalcoholic steatohepatitis, while JT-002 has been studied for conditions including Muckle-Wells syndrome. Both are early-stage compounds from Jecure Therapeutics.

Other names: JT-001 + JT-002

Targets

NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on JT-001 + JT-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JT-001 + JT-002.

Explore the full profile